Business
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J., January 05, 2026--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursuant to his previously announced employment agreement with the Company dated as of December 11, 2025.
About this update from Koru Medical Systems, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2974fc768bfc11c20935602407fea490"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hEAYUeYZMxAlwOR9xTZ.ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2974fc768bfc11c20935602407fea490","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/eBJQPsAYaEczJYwghFX3MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/2974fc768bfc11c20935602407fea490","width":1024,"height":512}},"lazy":false},{"type":"text","content":"MAHWAH, N.J., January 05, 2026--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursuant to his previously announced employment agreement with the Company dated as of December 11, 2025.","length":518,"tagName":"p"},{"type":"text","content":"Mr. Schiller was granted nonqualified stock options on January 2, 2026 to purchase 232,297 shares of the Company’s common stock at an exercise price of $5.70 per share. In addition, on January 2, 2026, Mr. Schiller received 76,426 restricted shares of the Company’s common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Schiller and the Company. The Compensation Committee of the Company’s Board of Directors approved the awards as an inducement material to Mr. Schiller’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).","length":709,"tagName":"p"},{"type":"text","content":"About KORU Medical Systems","length":26,"tagName":"p"},{"type":"text","content":"KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Fr...